about
Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injuryErythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stressARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia responseAnthropometric variables accurately predict dual energy x-ray absorptiometric-derived body composition and can be used to screen for diabetesChronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy.Ketamine does not produce relief of neuropathic pain in mice lacking the β-common receptor (CD131).Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury.Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury.What evidence supports use of erythropoietin as a novel neurotherapeutic?Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?Neuroprotective properties of epoetin alfa.Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling.Recombinant human erythropoietin for neuroprotection: what is the evidence?An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo.ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Discovery of a master regulator of injury and healing: tipping the outcome from damage toward repair.A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock.Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia.Erythropoietin both protects from and reverses experimental diabetic neuropathy.Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go?Erythropoietin as an antiapoptotic, tissue-protective cytokine.Erythropoietin therapy for acute stroke is both safe and beneficialErythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosisTNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injurySafety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot studyCornea nerve fiber quantification and construction of phenotypes in patients with fibromyalgia.Erythropoietin: not just about erythropoiesis.Erythropoietin modulation of astrocyte water permeability as a component of neuroprotectionSuppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin.Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing.ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors.Behavioral method for the treatment of idiopathic scoliosis.ARA 290 for treatment of small fiber neuropathy in sarcoidosis.The mast cell plays a central role in the immune system of teleost fish.Cytoarchitectural relationships between [3H]ouabain binding and mRNA for isoforms of the sodium pump catalytic subunit in rat brain.Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.
P50
Q24530090-D3B63750-6AC5-4A0A-9290-3D8B2E4C2089Q24611053-E1D1127B-BBA2-4B9D-B6FA-91B88CF18707Q28658933-62D0A2BC-7C5D-499B-97CF-FE577B3E3FE4Q28740744-0F464B8A-971F-4CC9-B984-7BF06CB73C95Q30539892-282BE848-B4BF-4E39-904D-697A1D786113Q31126222-ED16B392-98F5-4FFE-B6AD-484349338805Q34075461-80899ABB-D863-42E8-8116-6F5C8ADE9976Q34132516-3C73FE3F-BE2A-4C9B-A1D4-CB5B407FEADCQ34154511-E533C160-5DA5-48C6-AA2A-084ADFF3523AQ34504572-64421A29-224C-4E78-A20D-D80551C63EB1Q34506947-C3B3598D-DE31-4006-AD7A-A308C972D1F3Q34596211-2B610B74-1E05-44F1-9BAE-C94EB6B2F366Q34699514-39F937CF-7C6E-4EB3-A300-527C2C418D6CQ34960679-6D96F261-BB19-47B8-AB73-650B66C6DA9EQ35047697-D015DCC3-CC8B-451B-B859-CEAEE40AA307Q35081898-33DA44E2-2A7E-4920-9C16-F438FD09F3E8Q35144156-1F4649D9-5DCB-478E-B545-3F54AE72BDB2Q35192848-337FF263-DA2F-4D03-8D53-55F211BA4FD5Q35219021-F4C551FE-AD3A-48BE-A1C1-15D074EDC829Q35287077-6208842F-1C5F-47F0-9B42-0C72F34D6BCAQ35448895-A7C2B126-B8C8-45D2-A9F5-1BC7D5AB578AQ35554405-0ACADB1E-2684-4E2F-94BC-169788FF262CQ35740529-CB3999F3-7414-4F08-A40C-B476C6A952F3Q35831214-CDF9854A-2C2A-44FB-AD41-5B37BEE0C2F4Q36088111-CCEC4CB1-DB97-4083-9732-7F7068C98080Q36371706-73B1D788-C8CD-4A0A-A30A-8769C9569B7FQ36545939-771B5CFC-3832-426A-928F-90CF96AABD31Q36585607-14FBC74B-ED29-481F-859D-4C2637CDF3FFQ36719434-7919D6AD-9263-4142-8CDF-82725606CACFQ36972360-5CDA949A-0672-46EB-8AA0-B16AFAA69DA4Q37068999-0475DACF-3FBE-4113-B0B2-4D3E5CCCBB7AQ37100284-6652CCCF-E7E3-448F-9D55-6292BDAD469BQ37254556-EA0A67B7-CFD0-4A7D-930F-FFDCCD2EB1F7Q37446047-FC7C198F-F032-40CB-84A8-C82807B4FC5FQ37679592-0FA720F6-891B-4F3E-B401-3D160789B745Q37684957-1F6E6888-9F08-4EAD-9E64-E1F68EAD2D17Q38189862-7EFC2BAD-CAB3-4C11-9380-9AE6D03A405DQ38194788-388473BE-B81C-442D-8D7B-E0D1F7965AD9Q38335282-60DB8AE5-506A-4390-AA29-2A4499F14E4DQ38366450-409735C5-FB55-4C1A-BC47-692DF890A30D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael Brines
@ast
Michael Brines
@en
Michael Brines
@es
Michael Brines
@nl
Michael Brines
@sl
type
label
Michael Brines
@ast
Michael Brines
@en
Michael Brines
@es
Michael Brines
@nl
Michael Brines
@sl
prefLabel
Michael Brines
@ast
Michael Brines
@en
Michael Brines
@es
Michael Brines
@nl
Michael Brines
@sl
P106
P31
P496
0000-0003-4151-4449